药物基因检测指导的氯吡格雷个体化用药2例被引量：3

Individualized medication of clopidogrel guided by drug genetic testing in 2 cases

下载PDF

导出

摘要冠状动脉粥样硬化性心脏病(冠心病)患者经皮冠状动脉(冠脉)介入治疗(PCI)围手术期有效的抗血小板治疗十分重要,患者虽接受规范氯吡格雷联合阿司匹林双联抗血小板治疗,但仍可发生支架内血栓事件。氯吡格雷治疗后血小板残留高反应性(HRPR)为PCI后支架内血栓和主要心血管不良事件的主要原因之一[1]。研究表明,细胞色素P450 2C19(CYP2C19)基因多态性是冠心病患者口服氯吡格雷疗效及预后欠佳的主要影响因素[2]。因此个体化抗血小板治疗时,应对患者进行基因型检测,尽早识别血小板高反应人群,更换治疗药物或增加氯吡格雷剂量,可降低患者支架内血栓形成风险。

作者张晶何胜虎王大新陈之遥刘佳 Zhang Jing;He Shenghu;Wang Daxin;Chen Zhiyao;Liu Jia

机构地区江苏省苏北人民医院心内科苏州大学附属第一医院药学部江苏省苏北人民医院药学部

出处《中国循证心血管医学杂志》 2018年第12期1581-1582,共2页 Chinese Journal of Evidence-Based Cardiovascular Medicine

基金江苏省"六大人才高峰"资助项目(2016-WSN-280) 江苏省药学会-夏尔医院药学基金(S201714)

关键词氯吡格雷个体化用药治疗药物冠状动脉粥样硬化性心脏病基因检测支架内血栓形成抗血小板治疗 CYP2C19

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献2

1替格瑞洛临床应用中国专家共识[J].中华心血管病杂志,2016,44(2):112-120. 被引量：100
2邹俊,李欣,邓明凤,谢进,黄琳琳.氯吡格雷血小板反应多样性研究进展[J].药物不良反应杂志,2016,18(1):46-51. 被引量：13

二级参考文献92

1Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[ J]. N Engl J Med, 2009, 361 ( 11 ): 1045-1057. DOI: 10. 1056/ NEJMou0904327.
2Harem CW,Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) [ J ]. Eur Heart J, 2011 , 32 ( 23 ) : 2999-3054. DOI : 10.1093/eurheartj/ebr236.
3O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infaretion: a repart of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[ J]. J Am Coll Cardiol,2013,61 (4) :e78-e140. DOI: 10. 1016/j. jacc. 2012.11. 019.
4Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) [J]. Eur Heart J,2014,35(37) :2541-2619. DOI:10. 1093/eurheartj/ehu278.
5Amsterdam EA,Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines[ J ]. Circulation, 2014,130 ( 25 ) : e344-e426. DOI : 10. 1161/CIR. 0000000000000134,.
6Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCBI single nucleotide polymorphisms on outcomes of treatment with tieagrelor versus clopidogrel for acute coronary syndromes:a genetic substndy of the PLATO trial [ J ]. Lancet, 2010. 376 (9749) : 1320-1328. DO1 : 10. 1016/S0140-6736 ( 10) 61274-3.
7Li H, Butler K,Yang L, et al. Pharmacokinetics and tolerability of single and multiple doses of tieagrelor in healthy Chinese subjects : an open-label, sequential, two-cohort, single-centre study [ J]. Clin Drug Investig, 2012, 32 ( 2 ) : 87-97. DOI: 10. 2165/ 11595930.-000000000-00000.
8Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome[ J]. Nat Rev Cardiol, 2015,1;2 ( 1 ) : 30-47. DOI : 10. 1038/nreardio. 2014. 156.
9Bliden KP, Tantry US, Storey RF, et al. The eftect of ticagrelor versus clopidogrel on high on-treatment platelel reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies [ J ]. Am Heart J,2011,162 ( 1 ) : 160-165. DOI : 10. 1016/j. ahj. 2010. 11.0:25.
10Storey RF, Angiolillo D J, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes:the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy [J ]. J Am Coll Cardiol,2010,56( 18 ) :1456-1462. DOI: 10. 1016/j. jacc. 2010. 03. 100.